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Introduction {#s01}
============

PKD is characterized by the accumulation of multiple fluid-filled cysts in the kidneys and other organs. It is the most common inherited kidney disorder affecting an estimated 12.5 million people globally, and represents more than 5% of the worldwide total of end-stage renal disease \[[@bib-001]\]. PKD is transmitted as an autosomal dominant or autosomal recessive trait. Common features underlying PKD include the development of cysts and progressive impairment of renal function, but different types of PKD are distinguished from each other by different ages of onset, variable rates of renal disease progression, and a diverse array of extra-renal manifestations \[[@bib-001],[@bib-002]\]. The two major classes of PKD in humans are autosomal dominant (ADPKD) and autosomal recessive (ARPKD) \[[@bib-001],[@bib-003]\].

ADPKD is the most common form of PKD affecting 1 in 400--1000 live births \[[@bib-004]\], in which cyst development begins *in utero* and progresses slowly. The disease is often not clinically evident until after the third or fourth decade of adult life. Renal cysts also develop *in utero* in the less common recessive form of PKD, but in most cases recessive cystic kidney disease is more rapidly progressive, and is associated with congenital hepatic fibrosis \[[@bib-005]\].

In discussing the role of gene dosage effects in PKD, the focus of this article is on ADPKD caused by mutations in *PKD1* encoding polycystin-1 (PC1; 85% of cases) or *PKD2*, which encodes polycystin-2 (PC2; 10-15% of cases -- reviewed in \[[@bib-006]\]). The precise functional roles of PC1 and PC2 and their downstream effector pathways have yet to be determined. Current theoretical models suggest that germline mutations in *PKD1* or *PKD2*, coupled with somatic second hit mutations, lead to absent or reduced PC1 or PC2 expression levels, which affects the cell-cell adhesion, polarity of basolateral epithelial cell membranes, promotion of primary cilia functional or length abnormalities, and/or developmental defects of tubular epithelial cells \[[@bib-006]\].

The 2-hit model of cystogenesis in ADPKD {#s02}
========================================

The total number of cysts per kidney in patients who have mild to moderate ADPKD, with a mean age of 30.8 years, ranges from between 10-20 to over 200, with a mean number of 91 cysts \[[@bib-007]\]. Although every cell in the kidneys of ADPKD patients carries the same genetic germline mutation, only a very small percentage of the total number of the cells in each nephron becomes cystic. Moreover, severity of the ADPKD phenotype varies considerably from family to family, and how this clinical variability occurs in ADPKD is not very well understood \[[@bib-008]\]. Just over twenty years ago a hypothesis, known as the 2-hit model of cystogenesis, was proposed in order to try to explain why a small percentage of the total number of cells in ADPKD kidneys becomes cystic \[[@bib-009]\]. In this model, kidney cysts only begin forming upon loss of function of both alleles of *PKD1* or *PKD2*, analogous to loss of function of both alleles of a tumour suppressor gene function in hereditary cancers, with each cyst representing a single clone of dividing cells. Therefore, in this scenario the initiating *PKD1* mutation would be germline, while the second "hit" in *PKD1* would be somatic, and would be a pre-requisite for focal cyst development \[[@bib-010]\].

In support of the 2-hit model, combinations of germline and somatic mutations in *PKD1* have been observed in individual cysts of patients with autosomal dominant polycystic kidney disease type 1 (ADPKD1) \[[@bib-011]\], and similarly germline *PKD2* mutations and somatic *PKD2* mutations have been identified in individual cysts of ADPKD2 patients \[[@bib-012]\]. Furthermore, combined mutations involving germline *PKD2* mutations and somatic *PKD1* mutations have also been observed in a small number of human renal cysts in kidneys from PKD patients \[[@bib-012],[@bib-013]\]. In addition, the direct causality between somatic inactivation of *Pkd2* and cyst formation has been implicated in an adult mouse model of ADPKD \[[@bib-014]\]. In this model a modified *Pkd2* allele (*Pkd2^Ws25^*) was generated in mice by insertion of a disrupted *Pkd2* exon 1 in tandem with the wild type exon 1. The *Pkd2^Ws25^* mice expressed functional PC2, but were prone to genomic rearrangements, which converted the *Pkd2* allele to either a null or true wild type allele. The somatic conversion to a null allele (from *Pkd2^Ws25^* to *Pkd2^-/-^*) correlated with cyst formation in the kidney, liver and pancreas. Furthermore, the cyst lining cells did not express PC2, suggesting that the somatic loss of *Pkd2* was sufficient for cyst formation \[[@bib-014]\]. In summary, in ADPKD a germline mutation in either *PKD1* or *PKD2* may be combined with a somatic second hit in the remaining normal copy of the affected gene, leading to cellular recessive loss of function in both kidney tubules and bile ducts. When taken together, these observations provide strong evidence for the "2-hit" mutation model for cystogenesis in PKD.

Evidence for gene dosage effects {#s03}
================================

Despite strong supporting evidence, the 2-hit gene mutation model does not sufficiently explain a number of observations in humans or mice with ADPKD. For example, multiple studies have clearly demonstrated that PC1 expression (or *PKD1* mRNA levels) was not lost and sometimes was elevated in the majority of cysts in ADPKD patients \[[@bib-015]-[@bib-018]\]. Furthermore, gene dosage effects were implicated in PKD mouse models characterized with either reduced or increased expression of *Pkd1* or *Pkd2* \[[@bib-019]-[@bib-022]\]. Since discrepancies between PKD mouse models and human ADPKD patients have been noted \[[@bib-023]\], it is possible that such gene dosage effects in mice could theoretically be dismissed as a discrepancy between human ADPKD and *Pkd1* or *Pkd2* mouse models.

Somewhat more incontrovertibly, however, in recent studies of *PKD1-* and/or *PKD2-*associated ADPKD in patients, it has clearly been shown that PKD can also be explained by gene dosage effects in humans (see [Fig 1](#fig-001){ref-type="fig"}). Peter Harris\'s group at the Mayo Clinic, Rochester USA, has shown that heterogeneous alterations in *PKD1*, including incompletely penetrant mutations, could help to explain extreme variability observed in disease severity in patients with ADPKD. At the same time, these incompletely penetrant mutations raise questions about what would constitute a genetic "hit". In the first of two related papers the authors describe consanguineous families with relatively mild phenotypes \[[@bib-024],[@bib-025]\]. In one of the families in particular, two siblings were homozygous for the weakly pathogenic (so-called "hypomorphic") mis-sense variant R3277C (RC) in the *PKD1* gene and these individuals developed end-stage renal disease aged 62 and 75 years. Of course, the observation of homozygous RC allele mutations is inconsistent with a typical autosomal dominant inheritance pattern of ADPKD, suggesting that a different genetic mechanism is operating. Several other family members who were heterozygous for RC (consistent with an autosomal dominant inheritance pattern) had only a few renal cysts as adults. Moreover, in several unrelated families described by the authors, the same hypomorphic RC mis-sense mutation was again found, particularly in one family who exhibited more severe *in utero* onset of PKD, but this time it was combined with a more severely pathogenic mutation in *PKD1* \[[@bib-024],[@bib-025]\]. Thus, the RC allele in each of these individuals appeared to exhibit a low "potency" and was relatively mildly pathogenic, even when in a double dose, but it was able to induce severe *in utero* onset PKD when combined together with a strongly pathogenic *PKD1* mutation.

![Depiction of gene dosage changes in kidney cyst formation in ADPKD\
A) A segment of renal tubule from a normal individual, with a normal *PKD1* gene dosage as represented by the dark blue colour of each epithelial cell of the renal tubule. B) Events leading to cyst formation in a segment of renal tubule from an individual with a *PKD1* mutation, associated with reduced dosage of functional PKD1 protein as represented by the lighter blue colour of each epithelial cell of the renal tubule. Within one cell of the renal tubule segment a somatic event occurs that leads to further reduced dosage levels of PKD1 protein (represented by the very pale blue colour), which then leads to cyst formation.](medrep-06-24-g001){#fig-001}

In a follow-on paper the Harris group then developed a "knock-in" mouse model containing the RC variant allele and demonstrated that it was indeed a functionally hypomorphic allele capable of affecting the severity of ADPKD in mice \[[@bib-026]\]. They showed that, as expected, *Pkd1*^+/null^ mice were normal, whereas in contrast *Pkd1*^RC/null^ mice were viable and had rapidly progressive disease, and the *Pkd1*^RC/RC^ mice developed renal cysts only gradually. These findings therefore support a gene dosage model, but ask the question how can gene dosage effects (and by inference dosage of the protein encoded by the gene) be explained?

In general, strict control of the dosage level of certain gene products is required in cells, which may be facilitated via gene networks. Several recent papers have focused on gene networks in PKD, which will be discussed in the next paragraph (see [Table 1](#tbl-001){ref-type="table"}). It is also worth mentioning at this point that mice with *Pkd1* haploinsufficiency develop renal anomalies over time and are not normal \[[@bib-027]\]. Moreover, progressive cystogenesis occurs in transgenic mice expressing artificial microRNAs against *Pkd1* \[[@bib-028]\]. Most renal cysts in human ADPKD appear in adulthood, and interestingly, mice with renal conditional ablation of *Pkd1* after postnatal day 13 or adulthood have either mild or no renal cystic phenotype \[[@bib-029]-[@bib-031]\]. These studies suggest that a gene dosage model may be operating within the context of a developmental window. In summary, there is now convincing evidence in both humans and mice strongly suggesting that dosage mechanisms are operating with respect to *PKD1* function. However, it remains unclear how insufficient levels of PKD1 protein lead to ADPKD.

###### Gene interaction networks involving *Pkd1* or *Pkd2* that impact dosage sensitivity and cystogenesis

![](medrep-06-24-t001)

  Gene interaction network         Molecular interaction             Disease                    Reference
  -------------------------------- --------------------------------- -------------------------- -------------------------------
  *Dicer/Pkd1*                     *miR200* -- *Pkd1*                ADPKD                      \[[@bib-032]\]
  *PRKCSH/SEC63/Pkhd1/Pkd1/Pkd2*   Glucosidase IIb -- polycystin 1   Polycystic liver disease   \[[@bib-033]\]
  *PRKCSH/SEC63/Pkhd1/Pkd1/Pkd2*   SEC63p -- polycystin 1            Polycystic liver disease   \[[@bib-033]\]
  *PRKCSH/SEC63/Pkhd1/Pkd1/Pkd2*   --                                ARPKD                      \[[@bib-033]\]
  *Pkd1/Pkd2*                      Pkd1 -- Pkd2                      ADPKD                      \[[@bib-013]\]
  *c-Met/NF-κB/Wnt/Pax2/Pkd1*      --                                ADPKD                      \[[@bib-036]\] \[[@bib-037]\]

Abbreviations: ADPKD, autosomal dominant polycystic kidney disease; ARPKD, autosomal recessive polycystic kidney disease.

Gene networks in PKD {#s04}
====================

Interactions between two or more genes involving gene interaction networks have been shown to impact on *Pkd1* gene dosage and cyst formation in several studies. *Dicer 1* mutations were shown to modify the *Pkd1* mutant phenotype and reduce cystogenesis by reducing the levels of certain microRNAs, including miR200, which increased the dosage levels of PC1 \[[@bib-032]\]. In other investigations, genetic interactions were studied to reveal factors that were required for adequate expression of functional protein complexes involving PC1 or PC2. For example, mutations in *PRKCSH* or *SEC63* (which cause polycystic liver disease in humans) have been shown to modify the effect of mutations in *PKD1*, and were used to provide evidence that PC1 is the rate-limiting step in the progression of PKD and polycystic liver disease when *Prkcsh* or *Sec63* were inactivated. Furthermore, the authors showed that the effects of reduced PC1 dosage differ depending on which nephron segment is involved; upon a reduced dosage of PC1 the severity of PKD is enhanced primarily by the increased growth of collecting duct cysts \[[@bib-033]\] ([Table 1](#tbl-001){ref-type="table"}).

A gene network involving *PKD1* and *PKD2* has been suggested \[[@bib-012],[@bib-013]\], and links between PC1 dosage and PC2 protein levels in the primary cilia were recently shown. Using induced pluripotent stem cells derived from PKD patient kidney cysts, Freedman *et al.* showed that the expression of PC2 in the primary cilia correlated with the level of expression (dosage) of PC1 \[[@bib-034]\]. The function of PC2 has been identified as an intracellular calcium release channel \[[@bib-002]\] that can interact with PC1, and so in this scenario the function of PC2 is highly dependent on the function of PC1.

Extending this theme further, not only is the *Pkd1* gene known to interact with the *Pkd2* gene, it appears that the dosage of PC1 can also modify the severity of cystogenesis in other forms of PKD, such as ARPKD. Fedeles *et al.* showed that an increase in the dosage of PC1 was able to rescue the ARPKD phenotype. According to this scenario, it is possible that ARPKD may be amenable to therapies that increase the dosage or function of PC1 \[[@bib-033]\] ([Table 1](#tbl-001){ref-type="table"}).

Another example of a gene network in PKD was investigated in mice engineered to have a "del34" null mutation in *Pkd1* (*Pkd1^del34/del34^*), which exhibited rapid and severe renal cyst formation *in utero*, and perinatal embryonic lethality \[[@bib-035]\]. Remarkably, cyst formation in the *Pkd1^del34/del34^* null mice was much less severe when they also carried a mutation in another gene, called *Pax2*, which is known to play an important role in nephrogenesis \[[@bib-036]\]. The reduced dosage of functional *Pax2* in these mutant mice may be genetically equivalent to inhibiting signaling pathways regulating planar cell polarity, such as hepatocyte growth factor receptor (c-Met), nuclear factor kappa B (NF-kB), or Wnt signaling; these factors were shown to form a regulatory cascade positively activating *Pax2* expression in kidney tubules \[[@bib-037]\].

Summary {#s05}
=======

Gene dosage effects in PKD have emerged as playing an important role in the pathogenesis of PKD; it is likely that cyst formation within a given segment of renal tubular epithelium is a stochastic process, the probability of which increases as the functionality of PC1 and/or PC2 decreases. Following inheritance of alterations in *PKD1* or *PKD2* that either strongly or mildly reduce polycystin functionality, cysts may form through a stochastic process in the kidneys if additional somatic mutations are acquired in the remaining non-mutant copy of *PKD1* or *PKD2*, or in genes that modify the function of *PKD1* or *PKD2* ([Table 1](#tbl-001){ref-type="table"}). This raises questions about how altered functional polycystin protein levels cause the initiation of cyst formation, especially because, paradoxically, higher levels of PC1 can also lead to renal cyst formation \[[@bib-038]\]. It is very likely that other mechanisms are also associated with altered functional activity of polycystins, including epigenetic changes \[[@bib-039]\] (e.g. histone modification), or specific biochemical alterations that affect certain signaling pathways. Any of the mechanisms discussed could potentially lead to significant variation in disease severity amongst individuals with predisposing mutations. Finally, the identification of alterations in cells that occur as a result of gene dosage changes in the *PKD1* network might also suggest novel routes of therapeutic intervention for PKD.
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